Facilitating diagnosis of critical illness myopathy using muscle excitability testing
Prof. med. Werner J. Z'Graggen, Inselspital Bern
Abstract (Lay summary see below)
In this project, recently developed muscle excitability tests sensitive to membrane potential will be combined with conventional methods to investigate the pathogenesis of critical illness myopathy (CIM). CIM is a frequent and serious complication of intensive care, which results in weakness that delays weaning from mechanical ventilation and increases mortality as well as morbidity. The current criteria allow diagnosis of CIM only at an advanced stage. The lack of a tool for early diagnosis of evolving CIM impedes the conduction of therapeutic trials and can have a negative impact on the patient’s treatment regime. Furthermore, the role of neuromuscular blocking agents, which are routinely used in clinical practice, as a causative factor for CIM is still unclear. Using muscle excitability tests, we could recently show that early muscle membrane depolarization/sodium channel inactivation precedes the development of structural changes in CIM in an animal model of sepsis and that this technique might be used for early detection of the disease. The aim of the present project is twofold:
1. To prospectively evaluate the evolution and pathophysiologic characteristics of muscular abnormalities in patients during critical illness until the definite diagnosis of CIM according to the current criteria can be made. We hypothesize that structural damage is preceded by muscle membrane depolarization and that diagnosis of membrane depolarization is one of the first signs of evolving CIM.
2. To compare abnormalities in excitability parameters of muscle fibers depending on the exposure to neuromuscular blocking agents in order to determine if treatment with neuromuscular blocking agents is an additional risk factor for CIM.
The project is designed as a longitudinal prospective observational study. Patients with sepsis and/or systemic inflammatory response syndrome and patients under treatment with neuromuscular blocking agents will be evaluated repetitively using muscle excitability measurements until definite diagnosis of CIM is made. The current study proposal therefore provides the possibility of a tool for early detection of CIM before its clinical manifestations with the ultimate goal to improve treatment of affected patients.
Lay summary
Das Projekt hat das Ziel mittels der Methode der Muskelfaserexzitabilitätsmessung die „critical illness“-Myopathie zu erforschen. Die „critical illness“-Myopathie kann bei Patienten, welche eine intensivmedizinische Behandlung benötigen auftreten. Als Folge können Patienten oft erst verzögert von der künstlichen Beatmung entwöhnt werden und benötigen eine längere Rehabilitation. Bei schwerer Ausprägung ist die Erholung inkomplett und die Mortalität erhöht. Bis heute ist die Ursache der Erkrankung nicht geklärt und es existiert keine Therapie. Die Methode der Muskelfaserexzitabilitätsmessung kann Störungen der elektrischen Eigenschaften der Muskelfasermembran aufzeigen.
Unsere Forschungsgruppe konnte bereits zeigen, dass solche als eines der ersten Zeichen der „critical illness“-Myopathie auftreten. Das Projekt will einerseits dazu beitragen, die Diagnosestellung zu erleichtern und andererseits die Ursache weiter erforschen. Insbesondere wird untersucht ob Medikamente aus der Gruppe der Muskelrelaxantien die Entstehung begünstigen.
Projets
- Nouveaux projets de recherche dès 2024
- L'importance et les succès de la recherche
- Projets financés
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Brochure décrivant les projets
- SEAL Therapeutics AG
- Rencontres et séminaires
- Participation à des associations faîtières
- Les registres de patients
- Le réseau Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch